UnknownNot Applicable

Pancreatic Cancer Recurrence in the Netherlands

Netherlands1,750 participantsStarted 2014-01-01

Plain-language summary

The aim of this nationwide, observational cohort study is to evaluate current surveillance strategies after primary resection of pancreatic ductal adenocarcinoma (PDAC) in the Netherlands, with regard to the detection, treatment and survival of PDAC recurrence.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients undergoing a pancreatic resection (PPPD, Whipple, distal pancreatectomy or total pancreatectomy) for histologically proven PDAC in one of the 16 Dutch centers for pancreatic surgery Exclusion Criteria: * Patients with 30-day postoperative mortality

What they're measuring

Incidence of PDAC recurrence

Timeframe: Within a follow-up period up to 5 years

Patterns of PDAC recurrence

Timeframe: Within a follow-up period up to 5 years

Treatment of PDAC recurrence

Timeframe: Within a follow-up period up to 5 years

Survival

Timeframe: Within a follow-up period up to 5 years

Trial details

NCT IDNCT04605237

SponsorUMC Utrecht

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-07-01

Contact for this trial

Iris van Goor, MD

+31631917882 I.W.J.vanGoor-5@umcutrecht.nl

View on ClinicalTrials.gov More Pancreatic Ductal Adenocarcinoma trials